VKTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Viking Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.59 |
| 52 Week High | US$99.41 |
| 52 Week Low | US$11.55 |
| Beta | 0.99 |
| 11 Month Change | -32.60% |
| 3 Month Change | -19.73% |
| 1 Year Change | 328.26% |
| 33 Year Change | 877.51% |
| 5 Year Change | 618.44% |
| Change since IPO | 486.94% |
Recent News & Updates
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Recent updates
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09
Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29Shareholder Returns
| VKTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.1% | 2.5% | 2.2% |
| 1Y | 328.3% | 16.1% | 31.6% |
Return vs Industry: VKTX exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: VKTX exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| VKTX volatility | |
|---|---|
| VKTX Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VKTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VKTX's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 31 | Brian Lian | www.vikingtherapeutics.com |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.
Viking Therapeutics, Inc. Fundamentals Summary
| VKTX fundamental statistics | |
|---|---|
| Market cap | US$5.86b |
| Earnings (TTM) | -US$99.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-59.1x
P/E RatioIs VKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VKTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$99.15m |
| Earnings | -US$99.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VKTX perform over the long term?
See historical performance and comparison